Suggested remit - To appraise the clinical and cost effectiveness of ibrutinib within its marketing authorisation for treating diffuse large B-cell lymphoma
As you will be aware the Department for Health and Social Care has asked NICE to carry out an appraisal of ibrutinib combination therapy for untreated diffuse large B-cell lymphoma. However, the company have advised that they will not be seeking regulatory approval from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes
 
Status Suspended
Process STA 2018
ID number 997

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
16 November 2018 Suspended, As you will be aware the Department for Health and Social Care has asked NICE to carry out an appraisal of ibrutinib combination therapy for untreated diffuse large B-cell lymphoma. However, the company have advised that they will not be seeking regulatory approval from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes
17 September 2018 - 15 October 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
05 December 2017 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance